Media headlines about CytomX Therapeutics (NASDAQ:CTMX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. CytomX Therapeutics earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.3689262559738 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

CytomX Therapeutics (NASDAQ:CTMX) traded up 0.94% on Friday, hitting $13.98. 159,504 shares of the stock traded hands. The firm’s market cap is $515.40 million. CytomX Therapeutics has a 12-month low of $9.85 and a 12-month high of $20.02. The stock has a 50-day moving average of $14.70 and a 200-day moving average of $14.50.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.30. The company had revenue of $8.75 million for the quarter, compared to analyst estimates of $4.95 million. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. Analysts forecast that CytomX Therapeutics will post ($1.47) earnings per share for the current year.

CTMX has been the subject of several recent analyst reports. Jefferies Group LLC reissued a “buy” rating and set a $25.00 price objective on shares of CytomX Therapeutics in a report on Wednesday, April 26th. Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a report on Wednesday, May 3rd. HC Wainwright reissued a “buy” rating on shares of CytomX Therapeutics in a report on Monday, May 8th. ValuEngine lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Finally, Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, June 28th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $25.60.

COPYRIGHT VIOLATION WARNING: “CytomX Therapeutics (NASDAQ:CTMX) Getting Somewhat Positive Media Coverage, Analysis Shows” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/13/cytomx-therapeutics-nasdaqctmx-getting-somewhat-positive-media-coverage-analysis-shows.html.

In other CytomX Therapeutics news, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $15.47, for a total value of $38,675.00. Following the sale, the chief financial officer now owns 22,126 shares of the company’s stock, valued at approximately $342,289.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Frederick W. Gluck sold 5,000 shares of the business’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $14.61, for a total transaction of $73,050.00. The disclosure for this sale can be found here. Insiders sold a total of 39,343 shares of company stock worth $606,856 in the last three months. Insiders own 4.70% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.